Post‐COVID‐19 co‐morbidity of emerged <i>Lophomonas</i> infection and invasive pulmonary aspergillosis: First case report
Ali Sharifpour, Zakaria Zakariaei, Mahdi Fakhar, Elham Sadat Banimostafavi, Maryam Nakhaei, Mostafa Soleymani
Abstract
Due to long corticosteroid therapy in patients with COVID-19, in case of cough, dyspnea, and weight loss, emerging pulmonary aspergillosis and lophomoniasis should be ruled out.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)Pulmonary aspergillosisAspergillosisPulmonary infection2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Intensive care medicineImmunologyInternal medicinePathologyInfectious disease (medical specialty)DiseaseOutbreakInsects and Parasite Interactions